Erica F Lawson1, Laura Trupin2, Edward H Yelin2, Jinoos Yazdany2. 1. Department of Pediatrics, Division of Rheumatology, Box 0632, 550 16th Street, 5th floor, San Francisco, CA 94143-0632. Electronic address: lawsone@peds.ucsf.edu. 2. Department of Medicine, Division of Rheumatology, Box 0920, 3333 California St., Suite 270, San Francisco, CA 94143-0920.
Abstract
OBJECTIVE: To better understand why immunosuppressed individuals with systemic lupus erythematosus (SLE) fail to receive influenza and pneumococcal vaccines. METHODS: These cross-sectional data were derived from the 2009 cycle of the Lupus Outcomes Study (LOS), an annual longitudinal telephone survey of individuals with confirmed SLE. Respondents were included in the analysis if they had taken immunosuppressive medications in the past year. We assessed any prior receipt of pneumococcal vaccine and influenza vaccine in the past year, and then elicited reasons for not receiving vaccination. We used bivariate statistics and multivariate logistic regression to assess frequency and predictors of reported reasons for not obtaining influenza or pneumococcal vaccines. RESULTS: Among 508 respondents who received immunosuppressants, 485 reported whether they had received vaccines. Among the 175 respondents who did not receive an influenza vaccine, the most common reason was lack of doctor recommendation (55%), followed by efficacy or safety concerns (21%), and lack of time (19%). Reasons for not receiving pneumococcal vaccine (N = 159) were similar: lack of recommendation (87%), lack of time (7%), and efficacy or safety concerns (4%). Younger, less-educated, non-white patients with shorter disease duration, as well as those immunosuppressed with steroids alone, were at the greatest risk for not receiving indicated vaccine recommendations. CONCLUSIONS: The most common reason why individuals with SLE did not receive pneumococcal and influenza vaccines was that physicians failed to recommend them. Data suggest that increasing vaccination rates in SLE will require improved process quality at the provider level, as well as addressing patient concerns and barriers.
OBJECTIVE: To better understand why immunosuppressed individuals with systemic lupus erythematosus (SLE) fail to receive influenza and pneumococcal vaccines. METHODS: These cross-sectional data were derived from the 2009 cycle of the Lupus Outcomes Study (LOS), an annual longitudinal telephone survey of individuals with confirmed SLE. Respondents were included in the analysis if they had taken immunosuppressive medications in the past year. We assessed any prior receipt of pneumococcal vaccine and influenza vaccine in the past year, and then elicited reasons for not receiving vaccination. We used bivariate statistics and multivariate logistic regression to assess frequency and predictors of reported reasons for not obtaining influenza or pneumococcal vaccines. RESULTS: Among 508 respondents who received immunosuppressants, 485 reported whether they had received vaccines. Among the 175 respondents who did not receive an influenza vaccine, the most common reason was lack of doctor recommendation (55%), followed by efficacy or safety concerns (21%), and lack of time (19%). Reasons for not receiving pneumococcal vaccine (N = 159) were similar: lack of recommendation (87%), lack of time (7%), and efficacy or safety concerns (4%). Younger, less-educated, non-white patients with shorter disease duration, as well as those immunosuppressed with steroids alone, were at the greatest risk for not receiving indicated vaccine recommendations. CONCLUSIONS: The most common reason why individuals with SLE did not receive pneumococcal and influenza vaccines was that physicians failed to recommend them. Data suggest that increasing vaccination rates in SLE will require improved process quality at the provider level, as well as addressing patient concerns and barriers.
Authors: Elisha Brownfield; Justin E Marsden; Patty J Iverson; Yumin Zhao; Patrick D Mauldin; William P Moran Journal: Am J Infect Control Date: 2012-03-13 Impact factor: 2.918
Authors: E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin Journal: Lupus Date: 2003 Impact factor: 2.911
Authors: C M Thorburn; L Prokunina-Olsson; K A Sterba; R F Lum; M F Seldin; M E Alarcon-Riquelme; L A Criswell Journal: Genes Immun Date: 2007-03-08 Impact factor: 2.676
Authors: Sidha Sreedharan; Ning Li; Geoff Littlejohn; Russell Buchanan; Mandana Nikpour; Eric Morand; Alberta Hoi; Vera Golder Journal: Arthritis Res Ther Date: 2022-06-22 Impact factor: 5.606